OXFORD, Ohio and
COCONUT CREEK, Fla.,
March 23, 2022 /CNW/ -
PsyBio Therapeutics Corp. (TSXV: PSYB) (OTCQB: PSYBF)
("PsyBio" or the "Company"), an integrated and
intellectual property driven biotechnology company focusing on
discovering developing novel, bespoke psychoactive medicinal
candidates targeting the potential treatment of mental health
challenges, neurological disorders and other human health
conditions, today announces that Evan
Levine, Chief Executive Officer and Chairman, will
participate in the 2022 Maxim Group Virtual Growth Conference on
March 28-30, 2022.
PsyBio's presentation will be available to view on demand
beginning at 9:00 a.m. ET on Monday,
March 28th. To attend, please register here. To listen to the
presentation, please click here to access the webcast.
To schedule a meeting with the PsyBio management team, please
contact KCSA Strategic Communications by emailing
PsyBio@kcsa.com.
About PsyBio Therapeutics Corp.
PsyBio Therapeutics is fully integrated and intellectual
property driven biotechnology company developing novel psychoactive
medicinal candidates produced by genetically modified organisms
targeting the potential treatment of mental health challenges,
neurological disorders, and other human health conditions. The team
has extensive experience in drug discovery based on synthetic
biology and metabolic engineering as well as clinical and
regulatory expertise progressing drugs through human studies and
regulatory protocols. Research and development activities are
currently ongoing for naturally occurring psychoactive tryptamines
originally discovered in different varieties of hallucinogenic
mushrooms, other tryptamines and phenethylamines and combinations
thereof. The Company utilizes a bio-medicinal chemistry approach to
therapeutic development, in which psycho-targeted compounds can be
utilized as a template upon which to develop precursors and
analogs, both naturally and non-naturally occurring, specifically
because they are already known to have an effect within the
brain.
PsyBio makes no medical, treatment or health benefit claims
about PsyBio's proposed products. The U.S. Food and Drug
Administration ("FDA") or other similar regulatory
authorities have not evaluated claims regarding psilocybin and
other next generation psychoactive compounds. The efficacy of such
products has not been confirmed by FDA-approved research. There is
no assurance that the use of psilocybin and other psychoactive
compounds can diagnose, treat, cure, or prevent any disease or
condition. Vigorous scientific research and clinical trials are
needed. PsyBio has not conducted clinical trials for the use of its
intellectual property. Any references to quality, consistency,
efficacy and safety of potential products do not imply that PsyBio
verified such in clinical trials or that PsyBio will complete such
trials. If PsyBio cannot obtain the approvals or research necessary
to commercialize its business, it may have a material adverse
effect on the PsyBio's performance and operations.
The TSX Venture Exchange ("TSXV") has neither approved
nor disapproved the contents of this news release. Neither the TSXV
nor its Regulation Services Provider (as that term is defined in
the policies of the TSXV) accepts responsibility for the adequacy
or accuracy of this release.
SOURCE PsyBio Therapeutics Corp.